Physician profile
Yaser A Alkhatib
NPI 1194008235
$3,829.26
in general payments reported to CMS, 2019-2025
52 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $90.41 · 2023: $1,431 · 2024: $1,904 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.85 |
| Education | $216.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.82 | 2023-2025 | Enhertu, Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $373.95 | 2023-2025 | |
| Janssen Biotech, INC. | $300.43 | 2023-2025 | Erleada, Akeega, Darzalex |
| Pfizer INC. | $221.57 | 2023-2024 | |
| Sobi, INC | $177.41 | 2023-2024 | |
| Abbvie INC. | $165.97 | 2023-2024 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $143.87 | 2023-2025 | Opdivo |
| Astellas Pharma US INC | $132.75 | 2024 | Padcev, Xospata |
| Genzyme Corporation | $130.28 | 2023-2024 | |
| Gilead Sciences, INC. | $108.82 | 2023-2024 | |
| Taiho Oncology, INC. | $105.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.41 | 2020 | |
| Eisai INC. | $83.91 | 2023-2024 | |
| Celgene Corporation | $70.37 | 2023-2024 | Pomalyst, Reblozyl |
| Pharmaessentia USA Corporation | $69.64 | 2023-2024 | Besremi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $68.62 | 2023-2024 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $65.64 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Merck Sharp & Dohme LLC | $64.56 | 2024 | Keytruda, Lenvima, Reblozyl |
| Incyte Corporation | $62.15 | 2023-2024 | Monjuvi, Jakafi |
| Morphosys, US INC. | $59.74 | 2023-2024 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $57.45 | 2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $54.45 | 2023-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $50.10 | 2023-2024 | Xpovio |
| Stemline Therapeutics INC. | $49.15 | 2023-2024 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $48.60 | 2023-2024 | |
| Immunogen, INC. | $45.57 | 2023-2024 | Elahere, Elahere |
| Array Biopharma INC | $45.31 | 2024-2025 | Adcetris, Elrexfio, Bosulif |
| Mirati Therapeutics, INC. | $39.77 | 2024 | Krazati |
| Tempus Ai, INC | $39.43 | 2024-2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.58 | 2023-2025 | Gilotrif |
| Glaxosmithkline, LLC. | $36.62 | 2024 | Ojjaara |
| Boston Scientific Corporation | $35.46 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Tactile Systems Technology INC | $33.87 | 2025 | Nimbl, Flexitouch Plus |
| Puma Biotechnology, INC. | $29.32 | 2024 | |
| Myriad Genetic Laboratories, INC. | $29.04 | 2023 | Myrisk |
| Immunocore Limited | $29.02 | 2024 | Kimmtrak |
| Tersera Therapeutics LLC | $26.36 | 2024 | Zoladex |
| Rigel Pharmaceuticals, INC. | $25.98 | 2023 | Rezlidhia, Tavalisse |
| Servier Pharmaceuticals LLC | $24.77 | 2025 | |
| Springworks Therapeutics, INC. | $21.47 | 2024 | Ogsiveo |
| Adaptive Biotechnologies Corporation | $20.29 | 2023 | Clonoseq |
| Sirtex Medical INC | $20.03 | 2024 | Sir-Spheres Microspheres |
| Janssen Pharmaceuticals, INC | $19.90 | 2025 | Tecvayli, Talvey, Darzalex |
| Emd Serono, INC. | $18.08 | 2024 | |
| Pharming Healthcare, INC. | $17.97 | 2024 | Ruconest |
| Pharmacyclics LLC, An Abbvie Company | $17.66 | 2023 | Epkinly, Imbruvica |
| Amgen INC. | $16.62 | 2023 | Kyprolis |
| Sun Pharmaceutical Industries INC. | $15.47 | 2023 | Yonsa, Odomzo |
| Pharmaand Gmbh | $15.46 | 2025 | Rubraca |
| Tolmar, INC. | $15.46 | 2025 | Rubraca, Eligard |
| Shield Therapeutics INC | $13.40 | 2023 | Accrufer |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaser Alkhatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.